TrialPath
Recruiting

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

NCT06419348 · First Affiliated Hospital of Chongqing Medical University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
About this study
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Eligibility criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc). Exclusion Criteria: 1. Patients with PSMA negative expression. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Study design
Enrollment target: 30 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-05-20
Estimated completion: 2026-12-31
Last updated: 2025-06-04
Interventions
Drug: 99mTc-QULIC-5-P1
Primary outcomes
  • Diagnostic efficacy (15 days)
Sponsor
First Affiliated Hospital of Chongqing Medical University · other
Contacts & investigators
ContactXiaoyang Zhang, PhD · contact · zhangxy@mail.bnu.edu.cn · 023-89011755
All locations (1)
The First Affiliated Hospital of Chongqing Medical UniversityRecruiting
Chongqing, Chongqing Municipality, China
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer · TrialPath